When will the LGVN stock earnings be released?

Longeveron (LGVN) will report Q4 2025 results on 17 Mar 2026 at 16:00 EDT. The release is after regular NASDAQ trading and may move LGVN stock sharply on clinical updates and cash guidance.

What are the main LGVN stock risks to watch?

Primary risks for LGVN stock include negative EPS (**-0.98**), cash runway concerns, trial enrollment setbacks, and dilution from financing. Clinical-stage biotech exposure raises binary event risk around the Q4 report.

How does Meyka AI view LGVN stock right now?

Meyka AI rates LGVN **65.59/100** (Grade B, HOLD). The model flags mixed fundamentals and assigns a short-term forecast of **$0.36**, but this is a projection and not investment advice.

What price targets should investors consider for LGVN stock?

Consider a conservative near-term target **$0.50**, base **$1.50**, and a bull analyst target **$6.50** from MarketBeat. Targets depend on clinical and financing outcomes and are not guarantees.

US Stocks

LGVN Longeveron Inc. (NASDAQ) pre-market 17 Mar 2026: Q4 earnings catalyst

ByHuzaifa Zahoor March 17, 2026March 17, 2026

The LGVN stock is trading pre-market on 17 Mar 2026 as Longeveron Inc. prepares to release Q4 2025 results after market hours. Investors are watching price $0.89, volume 25,293,342, and the earnings release scheduled for 16:00 EDT. The company’s EPS is -0.98 and the trailing PE reads -0.91, so clinical readouts and cash guidance will drive the move. This earnings spotlight focuses on what numbers could change the stock’s short-term path and which catalysts traders should track in the NASDAQ United States session.